Your DUB household inside Populus recognition characterization development and also phrase patterns

Aim To validate the Acuros®XB (AXB) dose calculation algorithm for a 6 MV beam from the Varian TrueBeam treatment units. Background Currently Anisotropic Analytic Algorithm (AAA) is clinically used on authors' department but AXB could replace it for VMAT treatments in regions where inhomogeneities and free air are present. Materials and methods Two steps are followed in the validation process of a new dose calculation algorithm. The first is to check the accuracy of algorithm for a homogenous phantom and regular fields. Multiple fields of increasing complexity have been acquired using a Mapcheck diode array. The accuracy of the algorithm was evaluated using the gamma analysis method. The second is to validate the algorithm in the presence of heterogeneous media. Planar absolute dose was measured with GafChromic®EBT2 film and was compared with the dose calculated by AXB. Gamma analysis was performed between Mapcheck measurements and AXB dose calculations, at a range of clinical source-surface distance. Results For SSDs ranging from 80 to 100 cm, the results show a minimum pass rate of 95% between AXB and Mapcheck acquisition. For open 6 MV photon beam interacting with a phantom with an air gap, the agreement after the air gap between AXB and GafChromic®EBT2 is less than 1% in the 3 × 3cm2 field and less than 2% in the 10 × 10 cm2 field. Conclusions AXB has advanced modelling of lateral electron transport that enables a more accurate dose calculation in heterogeneous regions and, compared with AAA, improves accuracy between different density interfaces. This will be of particular benefit for head/neck treatments.Aim The aim of this study is to evaluate the effects of Zinc Oxide nanoparticles on dose enhancement factor using PRESAGE dosimeter and Monte Carlo simulation. Background High Z materials absorb X-ray remarkably. find protocol Among Nano-science, Zinc Oxide nanoparticles are interesting semiconductors, producing reactive oxygen species when irradiated by photons. Therefore, it seems that dose enhancement originating by incorporating ZnO NPs in irradiated volume would increase the therapeutic ratio. Materials and methods Initially, the PRESAGE dosimeter was fabricated and calibrated. Then Zinc Oxide nanoparticles with an average particle size of about 40 nm were synthesized. At next step, various concentrations of the nanoparticles were incorporated into the PRESAGE composition and irradiated in radiation fields. Then, the mentioned processes were simulated. Results Practical measurements revealed that by incorporating 500, 1000 and 3000 μg ml-1 ZnO NPs into PRESAGE the dose enhancement factor of 1.36, 1.39, 1.44 for 1 × 1 cm 2 field size, 1.39, 1.41, 1.46 for 2 × 2 cm 2 and 1.40, 1.45 and 1.50 for 3 × 3 cm 2 could be found, respectively. Simulation results showed that in the mentioned condition, the dose enhancement factor of 1.05, 1.08, 1.10 for 1 × 1 cm 2 field size, 1.06, 1.09, 1.10 for 2 × 2 cm 2 and 1.08, 1.11 and 1.13 for 3 × 3 cm 2 could be derived, respectively. Conclusion The results of this study showed that dose enhancement increases by increasing concentration of Zinc Oxide nanoparticles. Many reasons such as photoelectric, pair production effects and even Compton scattering can cause dose enhancement for megavoltage beams.Aim To investigate the impact of Acuros XB (AXB) algorithm in the deep-inspiration breath-hold (DIBH) technique used for treatment of left sided breast cancer. Background AXB may estimate better lung toxicities and treatment outcome in DIBH. Materials and methods Treatment plans were computed using the field-in-field technique for a 6 MV beam in two respiratory phases - free breathing (FB) and DIBH. The AXB-calculations were performed under identical beam setup and the same numbers of monitor units as used for AAA-calculation. Results Mean Hounsfield units (HU), mass density (g/cc) and relative electron density were -782.1 ± 24.8 and -883.5 ± 24.9; 0.196 ± 0.025 and 0.083 ± 0.032; 0.218 ± 0.025 and 0.117 ± 0.025 for the lung in the FB and DIBH respiratory phase, respectively. For a similar target coverage (p > 0.05) in the DIBH respiratory phase between the AXB and AAA algorithm, there was a slight increase in organ at risk (OAR) dose for AXB in comparison to AAA, except for mean dose to the ipsilateral lung. AAA predicts higher mean dose to the ipsilateral lung and lesser V20Gy for the ipsilateral and common lung in comparison to AXB. The differences in mean dose to the ipsilateral lung were 0.87 ± 2.66 % (p > 0.05) in FB, and 1.01 ± 1.07% (p less then 0.05) in DIBH, in V20Gy the differences were 1.76 ± 0.83% and 1.71 ± 0.82% in FB (p less then 0.05), 3.34 ± 1.15 % and 3.24 ± 1.17 % in DIBH (p less then 0.05), for the ipsilateral and common lung, respectively. Conclusion For a similar target volume coverage, there were important differences between the AXB and AAA algorithm for low-density inhomogeneity medium present in the DIBH respiratory phase for left sided breast cancer patients. DIBH treatment in conjunction with AXB may result in better estimation of lung toxicities and treatment outcome.Background Radiation with or without chemotherapy is the main treatment of nasopharyngeal carcinomas (NPC). Local recurrence is difficult to manage. Local control is dose-dependent. Aim To analyze the effect of an endocavitary brachytherapy boost after external beam radiation (EBRT) to decrease local recurrence. Material and methods Thirty patients with T0-T2 NPC were treated 70% T1, 20% T2 and 10% T0; 33.3% N0, 20% N1, 43.3% N2 and 3.3% N3; 90% were undifferentiated carcinoma. All they received a 192-Ir high dose rate brachytherapy (HDR-BT) boost after 60 Gy of EBRT. The Rotterdam applicator was used in most cases, 3-4 fractions of 3.75-3 Gy in two days. Results With median follow-up (FU) of 63 months, a single parapharyngeal failure resulted in local control of 100% at 3 years and 95% at 5 years. Local control for T0-1 was 100% and for T2 67% at five years (p = 0.02). Regional-free recurrence survival was 92% at 5 years. Metastasis-free survival was 84% at 5 years. All cases of metastasis had histopathology of undifferentiated.